Presidio engages Boehringer for Phase IIa HCV combo collaboration
This article was originally published in Scrip
Executive Summary
Following its October engagement and December divorce from BioCryst Pharmaceuticals, San Francisco-based Presidio Pharmaceuticals has entered into a collaboration with Boehringer Ingelheim to move its lead hepatitis C virus (HCV) drug candidate into Phase II.